Matthew O'Brien
Stock Analyst at Piper Sandler
(1.52)
# 2,489
Out of 4,667 analysts
29
Total ratings
66.67%
Success rate
6.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $140 → $115 | $109.27 | +5.24% | 12 | Jul 1, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $17 | $9.93 | +71.20% | 3 | May 8, 2024 | |
| PODD Insulet | Maintains: Neutral | $295 → $230 | $266.58 | -13.72% | 1 | Feb 24, 2022 | |
| KRMD KORU Medical Systems | Downgrades: Neutral | $9 → $4.5 | $3.65 | +23.29% | 1 | Jan 26, 2021 | |
| IART Integra LifeSciences Holdings | Maintains: Neutral | $53 → $47 | $22.93 | +104.97% | 8 | Oct 29, 2020 | |
| BAX Baxter International | Maintains: Overweight | $77 → $83 | $32.63 | +154.37% | 1 | Jul 27, 2018 | |
| ALGN Align Technology | Maintains: Overweight | $300 → $325 | $223.87 | +45.17% | 1 | May 24, 2018 | |
| DXCM DexCom | Reinstates: Overweight | $20 | $75.24 | -74.08% | 1 | May 22, 2017 | |
| MDXG MiMedx Group | Initiates: Overweight | $10 | $9.06 | +10.38% | 1 | Mar 3, 2017 |
Zimmer Biomet Holdings
Jul 1, 2024
Downgrades: Neutral
Price Target: $140 → $115
Current: $109.27
Upside: +5.24%
Alphatec Holdings
May 8, 2024
Maintains: Overweight
Price Target: $19 → $17
Current: $9.93
Upside: +71.20%
Insulet
Feb 24, 2022
Maintains: Neutral
Price Target: $295 → $230
Current: $266.58
Upside: -13.72%
KORU Medical Systems
Jan 26, 2021
Downgrades: Neutral
Price Target: $9 → $4.5
Current: $3.65
Upside: +23.29%
Integra LifeSciences Holdings
Oct 29, 2020
Maintains: Neutral
Price Target: $53 → $47
Current: $22.93
Upside: +104.97%
Baxter International
Jul 27, 2018
Maintains: Overweight
Price Target: $77 → $83
Current: $32.63
Upside: +154.37%
Align Technology
May 24, 2018
Maintains: Overweight
Price Target: $300 → $325
Current: $223.87
Upside: +45.17%
DexCom
May 22, 2017
Reinstates: Overweight
Price Target: $20
Current: $75.24
Upside: -74.08%
MiMedx Group
Mar 3, 2017
Initiates: Overweight
Price Target: $10
Current: $9.06
Upside: +10.38%